Updated ExteNET Data Raise Questions Over TKI Utility in HER2+ Breast Cancer Brain Metastases and the Future of Neratinib
January 6th 2021
Adam M. Brufsky, MD, PhD, discusses the updated findings from the ExteNET trial, the role of TKIs in treating patients with brain metastases, and unanswered questions that future research efforts should aim to address.